<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03430206</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-43220</org_study_id>
    <nct_id>NCT03430206</nct_id>
  </id_info>
  <brief_title>Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) Use in Pediatric Procedures</brief_title>
  <official_title>Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) Use in Pediatric Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      THRIVE (Transnasal Humidified Rapid-Insufflation Ventilatory Exchange) refers to the use of&#xD;
      high-flow nasal cannula to augment the ability to oxygenate and ventilate a patient under&#xD;
      general anesthesia. The use of high-flow nasal cannula oxygen supplementation during&#xD;
      anesthesia for surgical procedures has been a recent development in the adult population,&#xD;
      with limited data analyzing the pediatric population. This study will determine whether high&#xD;
      flow nasal cannula oxygen supplementation during surgical or endoscopic procedures can safely&#xD;
      prevent desaturation events in children under anesthesia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing select procedures in the LPCH operating rooms or ambulatory procedure&#xD;
      unit, as identified by review of the daily schedule will be reviewed for potential study&#xD;
      enrollment. Study personnel will work with preoperative nurses to identify potential&#xD;
      participants. When potential candidates are identified, the investigators will discuss with&#xD;
      the surgeon or proceduralist and request that he/she talk with patients about study&#xD;
      participation to introduce the idea. On the day of surgery, potential subjects will arrive to&#xD;
      preoperative intake areas and proceed through the usual preoperative processes. Once in the&#xD;
      preoperative intake area, potential participants will be approached by study personnel at&#xD;
      least 30 minutes prior to their scheduled procedure for further explanation of the study and&#xD;
      obtaining consent and assent. At this time, potential subjects will be evaluated for interval&#xD;
      changes in health that may exclude them from the study. A random number generator will be&#xD;
      used to enroll participants into either the usual care (control) or THRIVE (treatment) arm.&#xD;
      Control subjects will undergo their scheduled procedure and recovery with the usual care.&#xD;
      Treatment subjects will undergo the scheduled procedure, with the difference being that a&#xD;
      high-flow nasal cannula will be applied prior to the start of the procedure and removed&#xD;
      following the procedure's conclusion. While applied, the cannula will deliver high- flow rate&#xD;
      oxygen, air, or a mixture of variable oxygen concentration (21-100%) depending on the&#xD;
      surgical conditions and requirements. The rate will be set at 1-2L/kg/min with a maximum of&#xD;
      70L/min. Participants in the treatment arm will then proceed to the recovery area as usual.&#xD;
      Following recovery from anesthesia, a brief questionnaire will be provided to applicable&#xD;
      patients or their parents/guardians/representatives. The intraoperative vital signs and&#xD;
      post-operative course will be analyzed with any patient data stored in a deidentified manner&#xD;
      on Stanford- compliant encrypted devices.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 21, 2018</start_date>
  <completion_date type="Actual">October 2, 2018</completion_date>
  <primary_completion_date type="Actual">October 2, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients are randomized at time of enrollment to either the control or intervention arms.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Surgical Interruptions</measure>
    <time_frame>Duration of surgery (generally less than 2 hours)</time_frame>
    <description>Number of surgical interruptions defined by a pause in surgical procedures due to need to intervene, normalized to case length.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxygen Desaturation Index</measure>
    <time_frame>Duration of surgery (generally less than 2 hours)</time_frame>
    <description>Oxygen desaturation index is defined as the number of times a patient has a 4% decrease in saturation from a 120 second rolling mean for greater than 10 seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Oxygen Desaturation Events &lt;90% or Defined by a 5% Fall From Baseline if Baseline Saturation &lt; 94%.</measure>
    <time_frame>Duration of surgery (generally less than 2 hours)</time_frame>
    <description>Relative incidence of oxygen desaturation as measured by pulse oximetry by second adjusted for post surgical diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Oxygen Desaturation</measure>
    <time_frame>Duration of surgery (generally less than 2 hours)</time_frame>
    <description>Absolute incidence of oxygen desaturation less than 90% as measured by pulse oximetry by second</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Up to 12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End-Tidal Carbon Dioxide (ETCO2)</measure>
    <time_frame>Duration of surgery (generally less than 2 hours)</time_frame>
    <description>Ventilation was measured with transcutaneous carbon dioxide sensor</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Post-surgical Diagnosis</measure>
    <time_frame>Duration of surgery (generally less than 2 hours)</time_frame>
    <description>Location of lesion(s) according to post-surgical diagnosis</description>
  </other_outcome>
  <other_outcome>
    <measure>Gas Pain or Bloating</measure>
    <time_frame>Evaluated postoperatively in post-anesthesia recovery unit prior to discharge, which is about 60 minutes postoperatively.</time_frame>
    <description>Incidence of gas pain or bloating as measured by post-operative survey</description>
  </other_outcome>
  <other_outcome>
    <measure>Nasal Irritation</measure>
    <time_frame>Evaluated postoperatively in post-anesthesia recovery unit prior to discharge, which is about 60 minutes postoperatively.</time_frame>
    <description>Incidence of nasal irritation as measured by post-operative survey</description>
  </other_outcome>
  <other_outcome>
    <measure>Sinus Pressure / Pain</measure>
    <time_frame>Evaluated postoperatively in post-anesthesia recovery unit prior to discharge, which is about 60 minutes postoperatively.</time_frame>
    <description>Incidence of sinus pressure and/or pain as measured by post-operative survey</description>
  </other_outcome>
  <other_outcome>
    <measure>Headache</measure>
    <time_frame>Evaluated postoperatively in post-anesthesia recovery unit prior to discharge, which is about 60 minutes postoperatively.</time_frame>
    <description>Incidence of headache as measured by post-operative survey</description>
  </other_outcome>
  <other_outcome>
    <measure>Other Adverse Events</measure>
    <time_frame>Evaluated postoperatively in post-anesthesia recovery unit prior to discharge, which is about 60 minutes postoperatively.</time_frame>
    <description>Other adverse events as measured by post-operative survey</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Oxygen Deficiency</condition>
  <condition>Desaturation of Blood</condition>
  <condition>Hypoventilation</condition>
  <condition>Anesthesia; Adverse Effect</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control subjects will undergo their scheduled procedure and recovery with the usual care. Following recovery from anesthesia, a brief questionnaire will be provided to applicable patients or their parents / guardians / representatives.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment subjects will undergo the scheduled procedure, with the difference being that a high-flow nasal cannula will be applied prior to the start of the procedure and removed following the procedure's conclusion. While applied, the cannula will deliver high- flow rate oxygen, air, or a mixture of variable oxygen concentration (21-100%) depending on the surgical conditions and requirements. The rate will be set at 1-2L/kg/min with a maximum of 70L/min. Participants in the treatment arm will then proceed to the recovery area as usual. Following recovery from anesthesia, a brief questionnaire will be provided to applicable patients or their parents / guardians / representatives.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High-flow nasal cannula</intervention_name>
    <description>While applied, the cannula will deliver high-flow rate oxygen, air, or a mixture of variable oxygen concentration (21-100%) depending on the surgical conditions and requirements. The rate will be set at 2L/kg/min with a maximum of 70L/min. This will be only for the duration of the surgery or procedure.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pediatric patients less than or equal to 18 years old undergoing general anesthesia&#xD;
             for procedures or surgeries at Lucile Packard Children's Hospital.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy, absence of parent or legal guardian able to provide written consent for&#xD;
             study participation, anatomical or surgical contraindications (epistaxis, basilar&#xD;
             skull fractures or abnormalities, nasal surgery or obstruction, nasal fractures, nasal&#xD;
             vascular abnormalities), papillomatosis, tracheostomy, emergent surgery for which&#xD;
             application of HFNC might delay surgery or might result in increased aspiration risk.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas J Caruso, M.D., M.Ed.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Clinical Professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=372121&amp;isReview=true</url>
    <description>Anticipated Australian study of similar protocol</description>
  </link>
  <reference>
    <citation>Humphreys S, Rosen D, Housden T, Taylor J, Schibler A. Nasal high-flow oxygen delivery in children with abnormal airways. Paediatr Anaesth. 2017 Jun;27(6):616-620. doi: 10.1111/pan.13151. Epub 2017 Apr 10.</citation>
    <PMID>28393433</PMID>
  </reference>
  <reference>
    <citation>Doyle AJ, Stolady D, Mariyaselvam M, Wijewardena G, Gent E, Blunt M, Young P. Preoxygenation and apneic oxygenation using Transnasal Humidified Rapid-Insufflation Ventilatory Exchange for emergency intubation. J Crit Care. 2016 Dec;36:8-12. doi: 10.1016/j.jcrc.2016.06.011. Epub 2016 Jun 23.</citation>
    <PMID>27546740</PMID>
  </reference>
  <reference>
    <citation>Mir F, Patel A, Iqbal R, Cecconi M, Nouraei SA. A randomised controlled trial comparing transnasal humidified rapid insufflation ventilatory exchange (THRIVE) pre-oxygenation with facemask pre-oxygenation in patients undergoing rapid sequence induction of anaesthesia. Anaesthesia. 2017 Apr;72(4):439-443. doi: 10.1111/anae.13799. Epub 2016 Dec 30.</citation>
    <PMID>28035669</PMID>
  </reference>
  <reference>
    <citation>Humphreys S, Lee-Archer P, Reyne G, Long D, Williams T, Schibler A. Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE) in children: a randomized controlled trial. Br J Anaesth. 2017 Feb;118(2):232-238. doi: 10.1093/bja/aew401.</citation>
    <PMID>28100527</PMID>
  </reference>
  <reference>
    <citation>Gustafsson IM, Lodenius Ã…, Tunelli J, Ullman J, Jonsson Fagerlund M. Apnoeic oxygenation in adults under general anaesthesia using Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) - a physiological study. Br J Anaesth. 2017 Apr 1;118(4):610-617. doi: 10.1093/bja/aex036.</citation>
    <PMID>28403407</PMID>
  </reference>
  <reference>
    <citation>Desai N, Fowler A. Use of Transnasal Humidified Rapid-Insufflation Ventilatory Exchange for Emergent Surgical Tracheostomy: A Case Report. A A Case Rep. 2017 Nov 1;9(9):268-270. doi: 10.1213/XAA.0000000000000589.</citation>
    <PMID>28622152</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>January 20, 2018</study_first_submitted>
  <study_first_submitted_qc>February 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2018</study_first_posted>
  <results_first_submitted>July 16, 2020</results_first_submitted>
  <results_first_submitted_qc>August 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 6, 2020</results_first_posted>
  <last_update_submitted>August 3, 2020</last_update_submitted>
  <last_update_submitted_qc>August 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Thomas Caruso</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>high-flow</keyword>
  <keyword>nasal cannula</keyword>
  <keyword>laryngoscopy</keyword>
  <keyword>otolaryngology</keyword>
  <keyword>oxygen</keyword>
  <keyword>desaturation</keyword>
  <keyword>anesthesia</keyword>
  <keyword>pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoventilation</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We are discussing with other facilities conducting research similar in description to or study for a possible multi-center study. If such coordination takes place, we anticipate all deidentified data collected with participating investigators.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 9, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT03430206/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 9, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT03430206/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard of Care</title>
          <description>Control subjects will undergo their scheduled procedure and recovery with the usual standard care.</description>
        </group>
        <group group_id="P2">
          <title>THRIVE</title>
          <description>Participants received high flow nasal oxygen (THRIVE: active nasal oxygen delivery system).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants who completed the protocol are included in the analysis</population>
      <group_list>
        <group group_id="B1">
          <title>Standard of Care</title>
          <description>Control subjects will undergo their scheduled procedure and recovery with the usual standard care.</description>
        </group>
        <group group_id="B2">
          <title>THRIVE</title>
          <description>Participants received high flow nasal oxygen (THRIVE: active nasal oxygen delivery system).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="21"/>
                    <count group_id="B3" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.1" spread="4.6"/>
                    <measurement group_id="B2" value="6.6" spread="6.2"/>
                    <measurement group_id="B3" value="5.5" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="21"/>
                    <count group_id="B3" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="21"/>
                    <count group_id="B3" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="21"/>
                    <count group_id="B3" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown/Unreported</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="21"/>
                    <count group_id="B3" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="21"/>
                    <count group_id="B3" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percent Oxygen Saturation</title>
          <population>3 participants in the THRIVE group were missing baseline values</population>
          <units>Percent Saturation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99.7" spread="0.6"/>
                    <measurement group_id="B2" value="99.3" spread="1.5"/>
                    <measurement group_id="B3" value="99.5" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Surgical Interruptions</title>
        <description>Number of surgical interruptions defined by a pause in surgical procedures due to need to intervene, normalized to case length.</description>
        <time_frame>Duration of surgery (generally less than 2 hours)</time_frame>
        <population>Participants who completed the protocol are included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Control subjects will undergo their scheduled procedure and recovery with the usual standard care.</description>
          </group>
          <group group_id="O2">
            <title>THRIVE</title>
            <description>Participants received high flow nasal oxygen (THRIVE: active nasal oxygen delivery system).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Surgical Interruptions</title>
          <description>Number of surgical interruptions defined by a pause in surgical procedures due to need to intervene, normalized to case length.</description>
          <population>Participants who completed the protocol are included in the analysis</population>
          <units>Interruptions</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.645" lower_limit="0.308" upper_limit="1.35"/>
                    <measurement group_id="O2" value="0.302" lower_limit="0.121" upper_limit="0.753"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.206</p_value>
            <method>Regression, Negative Binomial</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxygen Desaturation Index</title>
        <description>Oxygen desaturation index is defined as the number of times a patient has a 4% decrease in saturation from a 120 second rolling mean for greater than 10 seconds</description>
        <time_frame>Duration of surgery (generally less than 2 hours)</time_frame>
        <population>Participants who completed the protocol are included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Control subjects will undergo their scheduled procedure and recovery with the usual standard care.</description>
          </group>
          <group group_id="O2">
            <title>THRIVE</title>
            <description>Participants received high flow nasal oxygen (THRIVE: active nasal oxygen delivery system).</description>
          </group>
        </group_list>
        <measure>
          <title>Oxygen Desaturation Index</title>
          <description>Oxygen desaturation index is defined as the number of times a patient has a 4% decrease in saturation from a 120 second rolling mean for greater than 10 seconds</description>
          <population>Participants who completed the protocol are included in the analysis</population>
          <units>Events</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" lower_limit="0.415" upper_limit="2.86"/>
                    <measurement group_id="O2" value="0.312" lower_limit="0.100" upper_limit="0.976"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.101</p_value>
            <method>Regression, Negative Binomial</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Oxygen Desaturation Events &lt;90% or Defined by a 5% Fall From Baseline if Baseline Saturation &lt; 94%.</title>
        <description>Relative incidence of oxygen desaturation as measured by pulse oximetry by second adjusted for post surgical diagnosis</description>
        <time_frame>Duration of surgery (generally less than 2 hours)</time_frame>
        <population>Participants who completed the protocol are included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Control subjects will undergo their scheduled procedure and recovery with the usual standard care.</description>
          </group>
          <group group_id="O2">
            <title>THRIVE</title>
            <description>Participants received high flow nasal oxygen (THRIVE: active nasal oxygen delivery system).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Oxygen Desaturation Events &lt;90% or Defined by a 5% Fall From Baseline if Baseline Saturation &lt; 94%.</title>
          <description>Relative incidence of oxygen desaturation as measured by pulse oximetry by second adjusted for post surgical diagnosis</description>
          <population>Participants who completed the protocol are included in the analysis</population>
          <units>Events</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.536" lower_limit="0.195" upper_limit="1.473"/>
                    <measurement group_id="O2" value="0.268" lower_limit="0.087" upper_limit="0.826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.371</p_value>
            <method>Regression, Negative Binomial</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Oxygen Desaturation</title>
        <description>Absolute incidence of oxygen desaturation less than 90% as measured by pulse oximetry by second</description>
        <time_frame>Duration of surgery (generally less than 2 hours)</time_frame>
        <population>This outcome measure was removed from the analysis plan during the course of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Control subjects will undergo their scheduled procedure and recovery with the usual standard care.</description>
          </group>
          <group group_id="O2">
            <title>THRIVE</title>
            <description>Participants received high flow nasal oxygen (THRIVE: active nasal oxygen delivery system).</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Oxygen Desaturation</title>
          <description>Absolute incidence of oxygen desaturation less than 90% as measured by pulse oximetry by second</description>
          <population>This outcome measure was removed from the analysis plan during the course of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adverse Events</title>
        <time_frame>Up to 12 hours</time_frame>
        <population>Participants who completed the protocol are included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Control subjects will undergo their scheduled procedure and recovery with the usual standard care.</description>
          </group>
          <group group_id="O2">
            <title>THRIVE</title>
            <description>Participants received high flow nasal oxygen (THRIVE: active nasal oxygen delivery system).</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events</title>
          <population>Participants who completed the protocol are included in the analysis</population>
          <units>Events</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.183" lower_limit="0.061" upper_limit="0.547"/>
                    <measurement group_id="O2" value="0.268" lower_limit="0.107" upper_limit="0.672"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.601</p_value>
            <method>Regression, Negative Binomial</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>End-Tidal Carbon Dioxide (ETCO2)</title>
        <description>Ventilation was measured with transcutaneous carbon dioxide sensor</description>
        <time_frame>Duration of surgery (generally less than 2 hours)</time_frame>
        <population>Participants who completed the protocol are included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Control subjects will undergo their scheduled procedure and recovery with the usual standard care.</description>
          </group>
          <group group_id="O2">
            <title>THRIVE</title>
            <description>Participants received high flow nasal oxygen (THRIVE: active nasal oxygen delivery system).</description>
          </group>
        </group_list>
        <measure>
          <title>End-Tidal Carbon Dioxide (ETCO2)</title>
          <description>Ventilation was measured with transcutaneous carbon dioxide sensor</description>
          <population>Participants who completed the protocol are included in the analysis</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.6" lower_limit="46.5" upper_limit="56.7"/>
                    <measurement group_id="O2" value="52.8" lower_limit="48.2" upper_limit="57.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.738</p_value>
            <method>Regression, Negative Binomial</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Post-surgical Diagnosis</title>
        <description>Location of lesion(s) according to post-surgical diagnosis</description>
        <time_frame>Duration of surgery (generally less than 2 hours)</time_frame>
        <population>Participants who completed the protocol are included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Control subjects will undergo their scheduled procedure and recovery with the usual standard care.</description>
          </group>
          <group group_id="O2">
            <title>THRIVE</title>
            <description>Participants received high flow nasal oxygen (THRIVE: active nasal oxygen delivery system).</description>
          </group>
        </group_list>
        <measure>
          <title>Post-surgical Diagnosis</title>
          <description>Location of lesion(s) according to post-surgical diagnosis</description>
          <population>Participants who completed the protocol are included in the analysis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Supraglottic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infraglottic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Both Supraglottic and Infraglottic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Gas Pain or Bloating</title>
        <description>Incidence of gas pain or bloating as measured by post-operative survey</description>
        <time_frame>Evaluated postoperatively in post-anesthesia recovery unit prior to discharge, which is about 60 minutes postoperatively.</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Nasal Irritation</title>
        <description>Incidence of nasal irritation as measured by post-operative survey</description>
        <time_frame>Evaluated postoperatively in post-anesthesia recovery unit prior to discharge, which is about 60 minutes postoperatively.</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Sinus Pressure / Pain</title>
        <description>Incidence of sinus pressure and/or pain as measured by post-operative survey</description>
        <time_frame>Evaluated postoperatively in post-anesthesia recovery unit prior to discharge, which is about 60 minutes postoperatively.</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Headache</title>
        <description>Incidence of headache as measured by post-operative survey</description>
        <time_frame>Evaluated postoperatively in post-anesthesia recovery unit prior to discharge, which is about 60 minutes postoperatively.</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Other Adverse Events</title>
        <description>Other adverse events as measured by post-operative survey</description>
        <time_frame>Evaluated postoperatively in post-anesthesia recovery unit prior to discharge, which is about 60 minutes postoperatively.</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 12 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Standard of Care</title>
          <description>Control subjects will undergo their scheduled procedure and recovery with the usual standard care.</description>
        </group>
        <group group_id="E2">
          <title>THRIVE</title>
          <description>Participants received high flow nasal oxygen (THRIVE: active nasal oxygen delivery system).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Emesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Nose Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Throat Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Nasal Pain</sub_title>
                <description>Unconfirmed</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Enrollment did not meet the threshold needed for statistical significance</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Thomas Caruso, MD, MEd</name_or_title>
      <organization>Stanford University</organization>
      <phone>(626) 275-0341</phone>
      <email>tjcaruso@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

